FDA Approves Oceana Therapeutics’ Solesta for Fecal Incontinence

Following FDA approval of Oceana Therapeutics’ Solesta, for patients with fecal incontinence, the company is launching the product for the U.S. market, according to an Oceana Therapeutics news release.

Advertisement

 

Solesta, an injectable gel delivered into the anal canal in an outpatient procedure, is a minimally invasive treatment option.

 

The FDA previously noted difficulties in treating fecal incontinence.

 

Related Articles on Incontinence:

FDA Approves Solesta to Treat Life-Altering Fecal Incontinence

FDA Gastroenterology and Urology Device Panel Approves Fecal Incontinence Product

USC Colorectal Surgeon Andreas Kaiser Named GI Journal Editor


 

 

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.